Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) (BASALT)
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
A PHASE2 clinical study on Hodgkin's Lymphoma, this trial is ongoing. The trial is conducted by Federal Research Institute of Pediatric Hematology, Oncology and Immunology and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2019 — Aug 2020 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
For direct contact, visit the study record on ClinicalTrials.gov .